1. Home
  2. NRIX vs RR Comparison

NRIX vs RR Comparison

Compare NRIX & RR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • RR
  • Stock Information
  • Founded
  • NRIX 2009
  • RR 2016
  • Country
  • NRIX United States
  • RR United States
  • Employees
  • NRIX N/A
  • RR N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • RR
  • Sector
  • NRIX Health Care
  • RR
  • Exchange
  • NRIX Nasdaq
  • RR Nasdaq
  • Market Cap
  • NRIX 750.4M
  • RR 715.2M
  • IPO Year
  • NRIX 2020
  • RR 2023
  • Fundamental
  • Price
  • NRIX $16.85
  • RR $3.01
  • Analyst Decision
  • NRIX Strong Buy
  • RR Strong Buy
  • Analyst Count
  • NRIX 14
  • RR 1
  • Target Price
  • NRIX $26.29
  • RR $6.00
  • AVG Volume (30 Days)
  • NRIX 1.8M
  • RR 23.6M
  • Earning Date
  • NRIX 10-09-2025
  • RR 08-11-2025
  • Dividend Yield
  • NRIX N/A
  • RR N/A
  • EPS Growth
  • NRIX N/A
  • RR N/A
  • EPS
  • NRIX N/A
  • RR N/A
  • Revenue
  • NRIX $83,687,000.00
  • RR $4,126,000.00
  • Revenue This Year
  • NRIX $58.48
  • RR $20.24
  • Revenue Next Year
  • NRIX N/A
  • RR $130.19
  • P/E Ratio
  • NRIX N/A
  • RR N/A
  • Revenue Growth
  • NRIX 48.32
  • RR N/A
  • 52 Week Low
  • NRIX $8.18
  • RR $0.52
  • 52 Week High
  • NRIX $23.09
  • RR $7.43
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 80.15
  • RR 31.46
  • Support Level
  • NRIX $12.43
  • RR $3.02
  • Resistance Level
  • NRIX $13.43
  • RR $3.51
  • Average True Range (ATR)
  • NRIX 0.97
  • RR 0.31
  • MACD
  • NRIX 0.32
  • RR -0.09
  • Stochastic Oscillator
  • NRIX 98.68
  • RR 13.29

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About RR Richtech Robotics Inc. Class B

Richtech Robotics Inc is a developer of new robotic technologies focused on transforming labor-intensive services in hospitality and other sectors currently experiencing unprecedented labor shortages. The company designs, manufacture and sells robots to restaurants, hotels, senior living centers, casinos, factories, movie theaters and other businesses. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company designs its robots to be friendly, customizable to client environments, and extremely reliable.

Share on Social Networks: